All articles by Vishnu Priyan
Vishnu Priyan
Xenon Pharmaceuticals reports data from trial of MDD therapy
XEN1101 was found to be well-tolerated, with comparable adverse event rates across all treatment groups.
Acadia Pharmaceuticals begins trial of Alzheimer’s psychosis drug
The trial is designed to analyse the safety and efficacy of 30mg and 60mg doses of ACP-204 versus those of placebo.
TC BioPharm receives FDA approval for AML cell therapy trial
OmnImmune is an allogeneic unmodified cell therapy that consists of activated and expanded gamma delta T-cells.
Roivant and Priovant’s lupus drug fails to meet trial endpoint
Based on brepocitinib’s favourable safety and tolerability profile in the trial, Priovant will advance it for other indications.
GSK reports positive data from Phase III multiple myeloma trial
Interim efficacy assessment data showed that the trial met the primary endpoint of progression-free survival.
Royal Free London and UCL recruit patients for liver disease app trial
The trial is supported by a £2m grant from the UK National Institute for Health and Care Research.
University of Queensland’s vaccine shows virus-neutralising effect in trial
The Queensland and Australian governments, as well as various partners, supported the trial of the re-engineered molecular clamp.
AIM ImmunoTech concludes dosing in Phase II post-Covid drug trial
The company anticipates reporting topline findings from the trial in the first quarter of next year.
FDA grants IND approval for Senhwa’s trial of Silmitasertib
The trial will analyse whether early treatment with Silmitasertib hinders CAP progression.
Immix to assess cell therapy in Phase Ib/IIa AL amyloidosis trial
The open-label trial is designed to assess the efficacy and safety of NXC-201.